Well -- the US FTC just cleared the bust-up to proceed, per Reuters:
. . . .Schering-Plough agreed to sell its rolapitant drug, a treatment for nausea and vomiting in chemotherapy patients, as part of a proposed consent order with the government. The rolapitant drug, which was in the process of being licensed, will be sold to Opko Health. . . .
Merck has agreed to sell its interest in Merial Ltd, an animal health business, to its French partner in the joint venture, Sanofi-Aventis (SASY.PA), in response to regulators' concerns, the FTC said. . . .
I'll post the consent decree shortly.
No comments:
Post a Comment